Novavax Global Commercial Operations and COVID-19 Vaccine Update

Q4 and FY2022 Financial results $ in millions Q4 Total Revenue Full Year Total Revenue $1,982 61% growth $357 $222 73% growth $1,146 Q4 2021 Q4 2022 FY2021 FY2022 novavax . FY 2022 total revenue of $2.0B reflects 73% growth over prior year • $1.3 billion in cash as of 12/31/2022 © 2023 NOVAVAX. All rights reserved. 21

View entire presentation